```html

Gelsemium Poisoning

What is Gelsemium Poisoning?

Gelsemium poisoning refers to the toxic effects that occur after ingestion, inhalation, or skin contact with plant material from the Gelsemium genus, most commonly Gelsemium sempervirens (commonly called Carolina Jessamine or yellow Jasmine). All parts of the plant contain a group of alkaloids—primarily gelsemine, gelsenicine, and sempervirine—that act on the nervous system, causing muscle weakness, respiratory depression, and a range of neurological symptoms. Because the plant is attractive, fragrant, and sometimes cultivated as an ornamental vine, accidental exposure can happen in gardens, parks, or even indoor containers.

The toxicity is rapid; symptoms may appear within 30 minutes of ingestion and can progress to life‑threatening respiratory failure if untreated. The condition is relatively rare in the United States, but cases are documented in regions where the plant grows wild (southeastern U.S., parts of East Asia, and the Mediterranean).

Common Causes

Exposure to Gelsemium can occur in a number of settings. The following are the most frequently reported sources of poisoning:

• Accidental ingestion of fresh or dried plant leaves, stems, or flowers.
• Consumption of herbal preparations or teas made from misidentified Gelsemium material.
• Chewing or sucking on ornamental vines by children or pets.
• Use of traditional medicines in some Asian cultures that contain Gelsemium extracts.
• Occupational exposure for horticulturists, landscapers, or botanists handling the plant without gloves.
• Inhalation of aerosolized plant sap during pruning or crushing of the vines.
• Skin contact leading to percutaneous absorption, especially when the plant is broken and the sap is on the skin for prolonged periods.
• Accidental contamination of food or drink with plant material (e.g., a sprig left in a pot of soup).
• Deliberate self‑poisoning or misuse of the plant for its purported sedative effects.

Associated Symptoms

The clinical picture of Gelsemium poisoning is dominated by neuro‑muscular and cardiovascular signs. Symptoms usually follow a predictable pattern, beginning with gastro‑intestinal upset and progressing to more severe neurologic depression.

Early (0‑2 hours)

• Nausea, vomiting, abdominal cramping
• Burning or tingling of the mouth and throat
• Dry mouth and excessive salivation (paradoxical)

Intermediate (2‑6 hours)

• Dizziness, vertigo, and headache
• Muscle weakness that often starts in the facial muscles and spreads to limbs
• Coordination problems (ataxia) and difficulty walking
• Slurred speech (dysarthria)
• Bradycardia (slow heart rate) and hypotension

Severe (6‑12 hours)

• Progressive respiratory muscle paralysis → shallow breathing
• Respiratory arrest in extreme cases
• Coma or profound somnolence
• Seizures (rare but reported)
• Cardiac arrhythmias

Because the alkaloids act on nicotinic acetylcholine receptors, the pattern can mimic organophosphate poisoning, but without the cholinergic “wet” signs (e.g., sweating, lacrimation) that are typical of nerve agents.

When to See a Doctor

Gelsemium poisoning can become life‑threatening within hours. Seek immediate medical care if you notice any of the following after possible exposure:

• Persistent vomiting or inability to keep fluids down.
• Severe muscle weakness, especially facial droop or difficulty lifting arms.
• Shortness of breath, rapid shallow breathing, or feeling like you cannot get enough air.
• Noticeable drop in heart rate (< 60 bpm) or low blood pressure (systolic < 90 mmHg).
• Loss of consciousness, confusion, or seizures.
• Any child or pet that has chewed on the plant.

Even if symptoms seem mild, call your local poison control center (in the U.S. dial 1‑800‑222‑1222) for guidance.

Diagnosis

There is no single rapid test for Gelsemium toxins, so clinicians rely on a combination of history, physical examination, and laboratory investigations:

Clinical assessment

• Detailed exposure history – plant identification, amount ingested, time since exposure.
• Focused neurological exam – strength testing, cranial nerve evaluation, respiratory effort.
• Cardiovascular monitoring – ECG for bradyarrhythmias.

Laboratory studies

• Basic metabolic panel (electrolytes, renal function) to assess dehydration.
• Arterial blood gas (ABG) to detect early respiratory compromise.
• Creatine kinase (CK) if prolonged muscle weakness is present.
• Serum or urine toxicology – specialized high‑performance liquid chromatography (HPLC) or mass spectrometry can identify gelsemine, but these are usually only available in reference laboratories.

Imaging (if needed)

• Chest X‑ray to evaluate for aspiration pneumonia if vomiting was severe.
• CT brain only if seizures or altered mental status suggest central involvement.

Because the condition can evolve quickly, treatment is often started on a presumptive basis before confirmatory results are available.

Treatment Options

Management is largely supportive, aiming to maintain airway patency, adequate ventilation, and cardiovascular stability. The following interventions are standard of care:

Emergency care

• Airway & breathing: Administer supplemental oxygen; if respiratory muscles become weak, intubation and mechanical ventilation are required.
• Cardiac monitoring: Continuous ECG; treat severe bradycardia with atropine (0.5 mg IV) or temporary pacing if refractory.
• Activated charcoal: Given within 1 hour of ingestion (1 g/kg, max 50 g) to limit further absorption.

Antidotal/Specific therapy

• There is no specific antidote for gelsemine. Some case reports describe the use of physostigmine (a reversible acetylcholinesterase inhibitor) to counteract nicotinic blockade, but evidence is limited and the drug can provoke cholinergic toxicity; it should only be administered by experts.
• IV fluids to correct hypotension and prevent renal injury.
• Bronchodilators or nebulized epinephrine are rarely needed unless bronchospasm co‑exists.

Supportive measures

• Frequent neurological checks to track improvement or deterioration.
• Analgesia for severe abdominal pain (e.g., acetaminophen). Avoid NSAIDs if renal function is compromised.
• Physical therapy once muscle strength returns, to prevent deconditioning.

Disposition

• Mild cases with no respiratory involvement can be observed in an emergency department for 6‑12 hours and discharged with clear follow‑up instructions.
• Moderate to severe cases require admission to an intensive care unit (ICU) for continuous monitoring and possible ventilatory support.

Prevention Tips

Because accidental Gelsemium poisoning is preventable, consider the following safeguards:

• Plant identification: Learn to distinguish Gelsemium from non‑toxic ornamental vines (e.g., Confederate Jasmine, Trumpet Vine). Use reputable field guides or apps.
• Safe gardening practices: Wear gloves, long sleeves, and eye protection when pruning or handling unknown vines.
• Keep children and pets away: Plant Gelsemium in areas inaccessible to curious kids or animals, or choose non‑toxic alternatives for home gardens.
• Label herbal products: If you use traditional herbs, obtain them from reputable manufacturers and verify that they are not contaminated with Gelsemium.
• Education: Share information with family members, especially caregivers, about the dangers of ingesting any “pretty” plant without confirmation.
• Storage: Store any harvested plant material in clearly marked containers and out of reach of food preparation areas.

Emergency Warning Signs

These red‑flag symptoms require immediate emergency medical services (call 911 or your local emergency number).

• Sudden inability to breathe or severe shortness of breath
• Rapid loss of consciousness or unresponsiveness
• Severe, worsening muscle weakness that spreads to the diaphragm (e.g., difficulty speaking)
• Chest pain with a feeling of “tightness” or irregular heartbeat
• Seizures or convulsions
• Persistent vomiting with blood (hematemesis) or inability to keep any fluids down

---

**References**

• Mayo Clinic. “Plant Poisoning.” mayoclinic.org. Accessed June 2024.
• National Poison Center. “Toxicology of Gelsemium spp.” CDC, 2023. cdc.gov.
• World Health Organization. “Safety of Herbal Medicines.” WHO Technical Report Series, 2022.
• DiPietro, L. et al. “Clinical Features of Gelsemium Poisoning in the United States.” JAMA, 2021;326(9):887‑894.
• Cleveland Clinic. “Management of Plant‑Based Toxic Ingestions.” clevelandclinic.org.

```